Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy

Max Kam-Kwan Chan; Emily Lok-Yiu Chan; Zoey Zeyuan Ji; Alex Siu-Wing Chan; Chunjie Li; Kam-Tong Leung; Ka-Fai To; Patrick Ming-Kuen Tang

doi:10.37349/etat.2023.00137

Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy

Max Kam-Kwan Chan, Emily Lok-Yiu Chan, Zoey Zeyuan Ji, Alex Siu-Wing Chan, Chunjie Li, Kam-Tong Leung, Ka-Fai To, Patrick Ming-Kuen Tang^*

^*Corresponding author for this work

Academy of Wellness and Human Development

Research output: Contribution to journal › Review article › peer-review

18 Citations (Scopus)

Abstract

Transforming growth factor-β (TGF-β) signaling is an important pathway for promoting the pathogenesis of inflammatory diseases, including cancer. The roles of TGF-β signaling are heterogeneous and versatile in cancer development and progression, both anticancer and protumoral actions are reported. Interestingly, increasing evidence suggests that TGF-β enhances disease progression and drug resistance via immune-modulatory actions in the tumor microenvironment (TME) of solid tumors. A better understanding of its regulatory mechanisms in the TME at the molecular level can facilitate the development of precision medicine to block the protumoral actions of TGF-β in the TME. Here, the latest information about the regulatory mechanisms and translational research of TGF-β signaling in the TME for therapeutic development had been summarized.

Original language	English
Pages (from-to)	316–343
Number of pages	28
Journal	Exploration of Targeted Anti-tumor Therapy
Volume	4
DOIs	https://doi.org/10.37349/etat.2023.00137
Publication status	Published - 28 Apr 2023

User-Defined Keywords

Transforming growth factor-β
tumor microenvironment
cancer
immunity
cancer immunotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.37349/etat.2023.00137

Cite this

@article{a3a58513dbc944f093f979db52e8971f,

title = "Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy",

abstract = "Transforming growth factor-β (TGF-β) signaling is an important pathway for promoting the pathogenesis of inflammatory diseases, including cancer. The roles of TGF-β signaling are heterogeneous and versatile in cancer development and progression, both anticancer and protumoral actions are reported. Interestingly, increasing evidence suggests that TGF-β enhances disease progression and drug resistance via immune-modulatory actions in the tumor microenvironment (TME) of solid tumors. A better understanding of its regulatory mechanisms in the TME at the molecular level can facilitate the development of precision medicine to block the protumoral actions of TGF-β in the TME. Here, the latest information about the regulatory mechanisms and translational research of TGF-β signaling in the TME for therapeutic development had been summarized.",

keywords = "Transforming growth factor-β, tumor microenvironment, cancer, immunity, cancer immunotherapy",

author = "Chan, {Max Kam-Kwan} and Chan, {Emily Lok-Yiu} and Ji, {Zoey Zeyuan} and Chan, {Alex Siu-Wing} and Chunjie Li and Kam-Tong Leung and Ka-Fai To and Tang, {Patrick Ming-Kuen}",

note = "Funding Information: This study was supported by the Research Grants Council of Hong Kong [RGC 14106518, 14111019, 14111720] RGC Postdoctoral Fellowship Scheme [PDFS2122-4S06] Health and Medical Research Fund [10210726] The Chinese University of Hong Kong{\textquoteright}s Faculty Innovation Award [4620528], Direct Grant for Research [4054510, 4054668], Postdoctoral Fellowship Scheme [NL/LT/PDFS2022/0360/22lt], CU Medicine Passion for Perfection Scheme [PFP202210-004] and Global Physician-Leadership Stream programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

month = apr,

day = "28",

doi = "10.37349/etat.2023.00137",

language = "English",

volume = "4",

pages = "316–343",

journal = "Exploration of Targeted Anti-tumor Therapy",

issn = "2692-3114",

publisher = "Open Exploration Publishing Inc",

}

TY - JOUR

T1 - Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy

AU - Chan, Max Kam-Kwan

AU - Chan, Emily Lok-Yiu

AU - Ji, Zoey Zeyuan

AU - Chan, Alex Siu-Wing

AU - Li, Chunjie

AU - Leung, Kam-Tong

AU - To, Ka-Fai

AU - Tang, Patrick Ming-Kuen

N1 - Funding Information: This study was supported by the Research Grants Council of Hong Kong [RGC 14106518, 14111019, 14111720] RGC Postdoctoral Fellowship Scheme [PDFS2122-4S06] Health and Medical Research Fund [10210726] The Chinese University of Hong Kong’s Faculty Innovation Award [4620528], Direct Grant for Research [4054510, 4054668], Postdoctoral Fellowship Scheme [NL/LT/PDFS2022/0360/22lt], CU Medicine Passion for Perfection Scheme [PFP202210-004] and Global Physician-Leadership Stream programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher copyright: © The Author(s) 2023.

PY - 2023/4/28

Y1 - 2023/4/28

N2 - Transforming growth factor-β (TGF-β) signaling is an important pathway for promoting the pathogenesis of inflammatory diseases, including cancer. The roles of TGF-β signaling are heterogeneous and versatile in cancer development and progression, both anticancer and protumoral actions are reported. Interestingly, increasing evidence suggests that TGF-β enhances disease progression and drug resistance via immune-modulatory actions in the tumor microenvironment (TME) of solid tumors. A better understanding of its regulatory mechanisms in the TME at the molecular level can facilitate the development of precision medicine to block the protumoral actions of TGF-β in the TME. Here, the latest information about the regulatory mechanisms and translational research of TGF-β signaling in the TME for therapeutic development had been summarized.

AB - Transforming growth factor-β (TGF-β) signaling is an important pathway for promoting the pathogenesis of inflammatory diseases, including cancer. The roles of TGF-β signaling are heterogeneous and versatile in cancer development and progression, both anticancer and protumoral actions are reported. Interestingly, increasing evidence suggests that TGF-β enhances disease progression and drug resistance via immune-modulatory actions in the tumor microenvironment (TME) of solid tumors. A better understanding of its regulatory mechanisms in the TME at the molecular level can facilitate the development of precision medicine to block the protumoral actions of TGF-β in the TME. Here, the latest information about the regulatory mechanisms and translational research of TGF-β signaling in the TME for therapeutic development had been summarized.

KW - Transforming growth factor-β

KW - tumor microenvironment

KW - cancer

KW - immunity

KW - cancer immunotherapy

U2 - 10.37349/etat.2023.00137

DO - 10.37349/etat.2023.00137

M3 - Review article

SN - 2692-3114

VL - 4

SP - 316

EP - 343

JO - Exploration of Targeted Anti-tumor Therapy

JF - Exploration of Targeted Anti-tumor Therapy

ER -

Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy

Abstract

User-Defined Keywords

UN SDGs

Access to Document

Fingerprint

Cite this